The Interest of the Xylocaine® and Ketamine on the Management of Acute and Chronic Ain After Colectomy by Laparoscopy

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Recent clinical studies in abdominal surgery have shown that the use of Xylocaine® parenterally intraoperative at plasma concentrations below the toxic threshold of 5 .mu.g / ml, had an analgesic effect and decreased postoperative morphine consumption.

This study aims to evaluate the activity of Xylocaine® and ketamine separately administered parenterally, in terms of postoperative morphine consumption and decrease incidences of postoperative chronic pain at 3 and 6 months after laparoscopic colectomy compared the placebo group.

The evaluation of the intensity of postoperative pain, hyperalgesia perished skin surface scarring) and pain perception threshold by Pain Matcher® confirm or not the predictive nature of these criteria in the occurrence of chronic pain.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Lille
• Treatments: Ketamine; Lidocaine

Criteria

Inclusion Criteria:

• Surgery: segmental or total colectomy performed by laparoscopy

• Anesthesia state 1 and 3

Exclusion Criteria:

• Patients classified Anesthesia state 4 or 5

• Allergy or intolerance to any of the products used in the protocol

• Creatinine clearance calculated by the Cockcroft formula below 50 ml / min

• Hepatocellular insufficiency

• Severe heart failure

• Peptic ulcer

• Chronic inflammatory bowel disease (IBD)

• Previous history of epilepsy or seizures

• Surgery emergency, palliative surgery, revision surgery

• Chronic pain requiring regular intake of analgesics include opioids

• Patients treated with lidocaine patch

• Psychic Disorder

• Additive Conduct vis-à-vis alcohol or mind-altering substances

• Pregnant or breastfeeding women